While solid evidence supports the chemopreventive role of 5-ASA and anti-TNFα in IBD patients, there is still a lack of long-term data on the safety and efficacy of newer biological therapies such as vedolizumab, ustekinumab, and tofacitinib. Here, TNF is linked to inflammatory bowel disease.